Nilo R.

Focus is placed on refractory focal and generalized epilepsies across pediatric and adult populations, seeking novel seizure control modalities.

• Adult Focal Epilepsy with drug‑resistant seizures
• Pediatric Childhood Absence Epilepsy requiring precision therapy
• Lennox‑Gastaut Syndrome in children and adolescents
• Refractory Juvenile Absence Epilepsy

Investigations target novel antiseizure compounds and device‑based neuromodulation.

Research addresses progressive neurodegeneration and lysosomal storage disorders, emphasizing disease‑modifying and gene‑based interventions.

• Alzheimer’s Disease cognitive decline pathways
• Huntington’s Disease gene‑silencing approaches
• Frontotemporal Dementia with progranulin mutations
• Niemann‑Pick disease type C disease‑modifying therapy
• MELAS mitochondrial dysfunction targeting

Therapeutic development includes disease‑modifying agents and gene‑based interventions.

Targeting primary and metastatic central nervous system malignancies, the investigator applies molecularly defined strategies to improve outcomes.

• Advanced Glioblastoma with targeted inhibitors
• ALK‑fusion positive CNS tumors under precision therapy
• Second‑line treatment for brain metastases in non‑small cell lung cancer
• Molecular profiling of CNS lesions for therapeutic matching

Precision oncology integrates targeted inhibitors and immunotherapies for CNS disease.

The investigator leverages biomarker‑driven approaches to align targeted agents with specific genetic alterations across neurological and oncological conditions.

• KRAS G12C targeted therapy in CNS tumors
• RET‑altered malignancies with central nervous system involvement
• ROS1‑positive lung cancer with brain spread
• NTRK‑fusion driven gliomas under selective inhibition
• EGFR mutation–guided strategies for metastatic disease

Therapeutic focus leverages selective inhibitors and combination regimens guided by genomic profiling.